OncoMatch/Clinical Trials/NCT06974929
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
Is NCT06974929 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including HRS-6209 Capsules and Letrozole Tablets for breast cancer.
Treatment: HRS-6209 Capsules · Letrozole Tablets · HRS-2189 Tablets — This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with other treatment regimens in breast cancer patients, and preliminarily observe its anti-tumor efficacy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic anti-tumor therapy
Evidence of radiographic disease progression during or after the last systemic anti-tumor therapy prior to the first study drug administration
Cannot have received: surgery
The patients received surgery...within 4 weeks before the first medication
Cannot have received: chemotherapy
The patients received...chemotherapy...within 4 weeks before the first medication
Cannot have received: immunotherapy
The patients received...immunotherapy...within 4 weeks before the first medication
Cannot have received: macromolecular targeted therapy
The patients received...macromolecular targeted therapy within 4 weeks before the first medication
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06974929 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior surgery, chemotherapy, immunotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages